Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19009039 | 0.83 | PIK3CD (0.35) | ATMKDM4E | |
| SCHEMBL19009041 | 0.82 | KDM4E (0.31) | KDM4E | |
| SCHEMBL14752148 | 0.82 | KDM4E (0.31) | KDM4E | |
| SCHEMBL19000154 | 0.76 | SLC6A9 (0.40) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11293431 | 0.74 | ATM (0.50) | MEN1KMT2AATMNPSR1TDP1 | |
| SCHEMBL27410749 | 0.72 | KDM4E (0.40) | MEN1KMT2AATMNPSR1TDP1 | |
| SCHEMBL19010252 | 0.72 | KDM4E (0.40) | MEN1KMT2AATMNPSR1TDP1 | |
| SCHEMBL27410751 | 0.72 | KDM4E (0.40) | MEN1KMT2AATMNPSR1TDP1 | |
| SCHEMBL23866534 | 0.71 | KDM4E (0.53) | MEN1KMT2AATMTDP1KDM4E | |
| SCHEMBL14754868 | 0.71 | CHRNB2 (0.35) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3888657-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2021-10-06 | — | — | EP | disclosed |
| EP-3513793-B1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE HOLDINGS CORP (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3513793-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-9730939-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3196202-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | Incyte Holdings Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9707233-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-9199982-B2 | Heterocyclylamines as PI3K inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340641-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | MEN1 2517/4885KMT2A 757/4885ATM 394/4885 |
| US-20160024117-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | MEN1 2517/4885KMT2A 757/4885ATM 394/4885 |
| US-20160022685-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | MEN1 2517/4885KMT2A 757/4885ATM 394/4885 |
| US-20130059835-A1 | HETEROCYCLYLAMINES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | MEN1 2517/4885KMT2A 757/4885ATM 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.